Sustained-release injection containing antibiotic danofloxain and uses thereof

A slow-release injection, dafloxacin technology, applied in the field of medicine, can solve the problems of side effects of increasing doses, difficulty in obtaining effective bactericidal concentration, etc., and achieve the effect of reducing the course of treatment, facilitating drug application, and reducing dosage

Inactive Publication Date: 2008-10-08
JINAN SHUAIHUA PHARMA TECH
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows for better delivery of certain types of medicine through controlled release systems such as slow releasing injectable devices like oxytazolidinone tablets. By placing these substances near areas where they are needed it will be more effective at delivering them throughout their body without causing harmful side effects.

Problems solved by technology

The technical problem addressed by this patented technology relates to finding novel ways to effectively kill resistant microorganisms such as those causing tuberculosis (TB). Current chemotherapies require longer periods before they work their way through these infectious diseases, leading them to developing multidrug-resistance strain(B) due to repeated use overtime. This makes current therapeutic strategies less efficient than necessary.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Put 90, 90 and 80 mg of polyphenylpropane (p-carboxyphenylpropane (p-CPP): sebacic acid (SA) at 20:80) copolymers into (A), (B) and (C) three Then add 100 milliliters of dichloromethane to each container, after dissolving and mixing, add 10 mg dafloxacin, 10 mg cephalexin, and 20 mg tylosin respectively, and prepare 10% Dafloxacin containing 10% Dafloxacin by spray drying method after re-shaking Flufloxacin, 10% cephalexin and 20% Tylosin microspheres for injection. Then suspend the microspheres in physiological saline containing 15% mannitol to prepare the corresponding suspension-type sustained-release injection. The viscosity of the injection is 300cp-600cp (at 20°C-30°C). The release time of the slow-release injection in physiological saline in vitro is 5-10 days, and the release time in mice subcutaneous is about 10-20 days.

Embodiment 2

[0112] The method step of being processed into slow-release injection is identical with embodiment 1, but difference is that contained antibacterial active ingredient and weight percentage thereof are:

[0113] (1) 2-50% apramycin, betamycin, dafloxacin, lincomycin, spectinomycin, doxycycline or streptomycin;

[0114] (2) 2-50% penicillin, difloxacin, aureomycin, carbadol, cloxacillin, marbofloxacin or pemafloxacin;

[0115] (3) 2-50% pilimycin, safloxacin, enunomycin, tylosin, cephalexin, ceftiofur or neomycin; or

[0116] (4) 2-50% salinomycin, novobiocin, ibafloxacin, gentamicin sulfate, sulfadiazine or sulfisoxazole.

Embodiment 3

[0118] Put 70 mg of polylactic acid (PLGA, 75:25) with a peak molecular weight of 10,000 into three containers (A), (B) and (C) respectively, and then add 100 ml of dichloromethane to each, dissolve and mix well , add 30mg lincomycin, 30mg doxycycline, 15mg lincomycin and 15mg doxycycline to three containers respectively, re-shake and use spray drying method to prepare 30% lincomycin, 30% doxycycline Injectable microspheres containing lincomycin, 15% lincomycin and 15% doxycycline. The dried microspheres are suspended in physiological saline containing 1.5% sodium carboxymethylcellulose to prepare the corresponding suspension-type sustained-release injection. The viscosity of the injection is 400cp-600cp (at 20°C-30°C). The drug release time of the slow-release injection in physiological saline in vitro is 7-15 days, and the drug release time in mice subcutaneous is about 15-25 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Viscosityaaaaaaaaaa
Login to view more

Abstract

The invention relates to a slow-release formulation containing danofloxacin as antibiotic, which is slow-released injection or slow-released implant; the injection is composed of a slow-released microsphere and dissolvent; the slow-released microsphere contains slow-released adjuvant and the antibiotic; the dissolvent is a special dissolvent containing suspending agent such as the sodium carboxymethylcellulose, etc. and the viscosity of the dissolvent is 100cp-3000cp (at the temperature of 20 DEG C-30 DEC C); the slow-released adjuvant is selected from EVAc, polifeprosan, PLA, PLGA, sebacic acid copolymer, albumen glue, gelatin, etc.; the slow-released implant is prepared with the slow-released microsphere or by other methods. The slow-release formulation can be partially placed or injected in a bacterial focus to release medicine on a partial disease focus for more than 10 days slowly; valid medicine concentration on the partial focus is obtained and maintained effectively, at the same time toxicity on an entire body is reduced remarkably. The slow-release formulation containing the danofloxacin as the antibiotic has a remarkable and special treatment effect on infection caused by staphylococcus, streptococcus, peptostreptococcus, propionibacterium acnes, enterobacter, tubercle bacillus, gonococci and meningococcus, etc., and particularly the partial focus such as chronic osteomyelitis, severe bedsore, refractory skin ulcer, diabetic foot, femoral head necrosis and various abscesses, etc.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner JINAN SHUAIHUA PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap